13 completed, 7 unknown, 4 recruiting, 2 not yet recruiting. 28 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 28 | Completed 13, Unknown 7, Recruiting 4, Not yet recruiting 2, Terminated 2 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mazdutide for Weight Management and Gout in Adults With Obesity Mazdutide - Gout, Obesity (BMI>30) | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2026-09-15 | 2026-09-17 |
| SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial Empagliflozin 10 mg, Placebo - Gout and Hyperuricemia | Phase 4 | Recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-08-05 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| Effect of Dotinurad in Hyperuricemia With Hypertension Dotinurad, Febuxostat - Hyperuricemia or Gout, Hypertension | Phase 4 | Recruiting | Saga University | 360 | 2025-03-28 | 2025-12-15 |
| CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea Continuous positive airway pressure, Hygienic-dietary recommendations and daily physical activity promotion - Sleep Apnea, Dyslipidemias | Phase 4 | Recruiting | Hospital Universitario La Paz | 220 | 2024-07-12 | 2024-07-15 |
| Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets Sodium Bicarbonate Oral Capsule, Potassium Citrate Tablets, uric-acid-lowering drug - Hyperuricemia or Gout, Nephrolithiasis | Phase 4 | Recruiting | Huashan Hospital | 312 | 2024-04-10 | 2025-05-13 |
| Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia Kui-Yuan Chewable Tablets, Placedo of Kui-Yuan Chewable Tablets - Hyperuricemia | Phase 4 | Unknown | Quan Jiang | 126 | 2023-07-01 | 2023-06-22 |
| Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention - Non-Alcoholic Fatty Liver Disease, Hyperuricemia | Phase 4 | Completed | Ain Shams University | 90 | 2022-01-01 | 2023-08-01 |
| Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia Aliskiren, Losartan - Hypertension,Essential, Hyperuricemia | Phase 4 | Completed | Hansung University | 66 | 2021-05-01 | 2024-12-05 |
| Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Febuxostat 40 mg, Benzbromarone 50mg, Control - Hyperuricemia, Metabolic Syndrome | Phase 4 | Unknown | National Defense Medical Center, Taiwan | 120 | 2020-02-01 | 2020-04-28 |
| Nutraceutical on Hyperuricemia Uricemin, Placebo - Hyperuricemia | Phase 4 | Completed | University of Pavia | 116 | 2018-10-01 | 2020-11-10 |
| The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet - Gout, CKD Stage 1-4 | Phase 4 | Unknown | Medical Practice Prof D. Ivanov | 2 | 2017-10-30 | 2022-08-24 |
| Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Febuxostat, Placebo - Hyperuricemia | Phase 4 | Unknown | Sun Yat-sen University | 548 | 2017-07-11 | 2020-10-22 |
| The Intervention of Multi-vitamin With Minerals to Hyperuricemia High-dose multi-vitamins with minerals, Low-dose multi-vitamins with minerals, Hypouricemic tablets - Hyperuricemia | Phase 4 | Unknown | Sun Yat-sen University | 200 | 2017-01-01 | 2017-07-14 |
| Effect of Hyperuricaemia on Chronic Renal Disease 20mg Febuxostat, 40mg Febuxostat - Hyperuricemia, Chronic Renal Disease | Phase 4 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 400 | 2017-01-01 | 2018-02-07 |
| The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Allopurinol, Placebo - Chronic Gout, Hyperuricemia | Phase 4 | Completed | University of California, San Francisco | 27 | 2016-11-01 | 2020-06-23 |
| Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine - Gout | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 196 | 2015-08-17 | 2019-06-21 |
| Pharmacogenetics of SGLT2 Inhibitors Canagliflozin - Diabetes Mellitus, Gout | Phase 4 | Terminated | University of Maryland, Baltimore | 30 | 2015-06-01 | 2022-08-02 |
| Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Anthocyanidins capsule, Placebo capsule, Allopurinol - Cardiovascular Disease | Phase 4 | Unknown | Guangzhou General Hospital of Guangzhou Military Command | 320 | 2015-01-01 | 2016-06-13 |
| the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Febuxostat - Coronary Artery Disease | Phase 4 | Terminated | Yokohama City University Medical Center | 1 | 2014-10-01 | 2017-08-03 |
Showing 20 of 28. Sign in to see all of them.
Gout (8) · Hypertension (3) · Cardiovascular Diseases (2) · Heart Failure (2) · Metabolic Syndrome (2) · Arthritis (1) · Arthritis, Gouty (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Dyslipidemias (1) · Essential Hypertension (1) · Inflammation (1) · Insulin Resistance (1) · Leukemia (1)
Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Metabolic Diseases (11) · Nutritional and Metabolic Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Crystal Arthropathies (8) · Genetic Diseases, Inborn (8) · Joint Diseases (8) · Metabolism, Inborn Errors (8) · Musculoskeletal Diseases (8) · Purine-Pyrimidine Metabolism, Inborn Errors (8) · Rheumatic Diseases (8) · Arthritis (7) · Cardiovascular Diseases (7) · Glucose Metabolism Disorders (4)
Febuxostat (10) · Allopurinol (9) · rasburicase (3) · Benzbromarone (2) · Anthocyanins (1) · Canagliflozin (1) · Colchicine (1) · Continuous Positive Airway Pressure (1) · Hydrochlorothiazide (1) · Losartan (1) · Minerals (1) · Naproxen (1) · Omeprazole (1) · Perindopril (1) · Pharmaceutical Preparations (1)
Sanofi (3) · Sun Yat-sen University (2) · Ain Shams University (1) · Anna Posadzy-Małaczyńska (1) · Getz Pharma (1) · Guangzhou General Hospital of Guangzhou Military Command (1) · Haiphong University of Medicine and Pharmacy (1) · Hansung University (1) · Hebei Medical University (1) · Hongwei Jiang (1) · Hospital Universitario La Paz (1) · Huashan Hospital (1) · Massachusetts General Hospital (1) · Medical Practice Prof D. Ivanov (1) · Menarini International Operations Luxembourg SA (1)
China (7) · Japan (3) · United States (3) · Italy (2) · Brazil (1) · Egypt (1) · Germany (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Romania (1) · Serbia (1) · South Korea (1) · Spain (1) · Taiwan (1)
Cheng-Wei Liu, M.D. (1) · Choe Seong Choon (1) · Claudio Borghi, Prof (1) · Dong Sun, MD (1) · Hongwei Jiang, MD (1) · Hyon K Choi, MD, DrPH (1) · Jaderson Lima (1) · Kathleen Giacomini, PhD (1) · Kazuhide Ogino, MD (1) · Khalid Mahmood, FCPS (1) · Kiyoshi Hibi, MD (1) · Koichi Node, Pr.,Dr. (1)
PMID 12421831, PMID 15698861, PMID 18349746, PMID 19933411, PMID 21849262, PMID 23395281, PMID 31033362, PMID 33040002, PMID 36945579, PMID 36993363
2014 (1), R01DK103729 (1), R21DK105401 (1), R61AR084188 (1)